BridgeBio Pharma Cost of Goods Sold 2018-2024 | BBIO
BridgeBio Pharma cost of goods sold from 2018 to 2024. Cost of goods sold can be defined as the difference between beginning and ending inventories for tangible products resulting in an expense that reflects production and sales costs.
BridgeBio Pharma Annual Cost of Goods Sold
(Millions of US $) |
| 2023 |
$2 |
| 2022 |
$3 |
| 2021 |
$3 |
| 2020 |
$ |
| 2019 |
$3 |
| 2018 |
$ |
| 2017 |
$ |
BridgeBio Pharma Quarterly Cost of Goods Sold
(Millions of US $) |
| 2024-06-30 |
$1 |
| 2024-03-31 |
$1 |
| 2023-12-31 |
$1 |
| 2023-09-30 |
$1 |
| 2023-06-30 |
$1 |
| 2023-03-31 |
$1 |
| 2022-12-31 |
$1 |
| 2022-09-30 |
$1 |
| 2022-06-30 |
$1 |
| 2022-03-31 |
$1 |
| 2021-12-31 |
$2 |
| 2021-09-30 |
$1 |
| 2021-06-30 |
$0 |
| 2021-03-31 |
|
| 2020-12-31 |
|
| 2020-09-30 |
|
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
|
| 2019-09-30 |
$3 |
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.629B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
